EDINBURGH, Scotland, Aug. 28,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
the closing of its previously announced public offering, upsized to
6,000,000 shares of its American Depository Shares ("ADSs")(or
pre-funded warrants in lieu thereof), together with Series H
warrants ("Series G Warrants") to purchase up to 6,000,000 ADSs at
a combined public offering price of $1 per ADS (or
pre-funded warrant in lieu thereof) and associated Series H
Warrant. The Series H Warrants have an exercise price of
£0.76 per ADS, are exercisable upon issuance and will expire one
year from the date of issuance. Each ADS represents two
hundred ordinary shares of the Company.
The gross proceeds to the Company from the
offering are $6.0 million, before
deducting offering expenses payable by the Company. The
Company intends to use the net proceeds from this offering to
support its upcoming clinical trial focusing on relapse/refractory
Acute Myeloid Leukemia, for market awareness and for continuing
operating expenses and working capital.
The securities described above are being offered
by the Company pursuant to a registration statement on Form F-1
(File No. 333-281613) previously filed with and declared effective
by the U.S. Securities and Exchange Commission ("SEC") on
August 28, 2024 and an additional
registration statement on Form F-1 filed pursuant to Rule 462(b)
which became automatically effective on August 28, 2024. . The offering was made
only by means of a prospectus, which is part of the effective
registration statement. A final prospectus relating to the offering
will be filed with the SEC. Electronic copies of the final
prospectus may be obtained for free on the SEC's website located
at http://www.sec.gov.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
other jurisdiction.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this Current Report
on Form 8-K that do not relate to matters of historical fact should
be considered forward-looking statements, including without
limitation statements regarding the Company's intent or ability to
affect any budget savings or execute on any M&A or capital
raising strategy. These statements are based on management's
current assumptions and are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC
website at www.sec.gov. All forward-looking statements reflect
the Company's beliefs and assumptions only as of the date of this
press release. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of gamma-delta T cell therapies for the treatment of cancer with
human efficacy data in acute myeloid leukemia. Gamma-delta T cells
are naturally occurring immune cells that embody properties of both
the innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC
BioPharm is the leader in developing gamma-delta T cell therapies,
and the first company to conduct phase II/pivotal clinical studies
in oncology. The Company is conducting two investigator-initiated
clinical trials for its unmodified gamma-delta T cell product line
- Phase 2b/3 pivotal trial in
treatment of acute myeloid leukemia using the Company's proprietary
allogeneic CryoTC technology to provide frozen product to clinics
worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-closing-of-upsized-6-0-million-public-offering-302233454.html
SOURCE TC BioPharm
